| Dr Bhaswanth Dhanireddy, MD | |
|
9301 W 74th St Ste 100, Shawnee Mission, KS 66204-2217 | |
| (913) 632-9100 | |
| (913) 632-9159 |
| Full Name | Dr Bhaswanth Dhanireddy |
|---|---|
| Gender | Male |
| Speciality | Radiation Oncology |
| Experience | 15 Years |
| Location | 9301 W 74th St Ste 100, Shawnee Mission, Kansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679972467 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0001X | Radiology - Radiation Oncology | 04-41946 (Kansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Adventhealth Shawnee Mission | Shawnee mission, KS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Shawnee Mission Medical Center Inc | 9537119037 | 177 |
News Archive
Verde Media Group Inc. and its Biotech Division announce they have completed the acquisition of the privately held biotechnology company Butazyme LLC.
Today, the American College of Rheumatology released the 2020 Guideline for the Management of Gout.
Claritas Genomics, Inc., announced the launch of its Claritas Clinical Exome, at the Annual Meeting of the American Society of Human Genetics running 10/6 – 10/10 in Baltimore, MD. This novel diagnostic test is the first to exploit the strengths of multiple DNA sequencing platforms simultaneously to deliver confirmed results for a patient's clinical whole exome within 4 weeks, compared to the industry standard of 12 weeks or more. Patients with rare disease typically seek a diagnosis for 8-12 years, receiving 3-5 separate tests at a high cost.
PrognosDx Health, Inc. announced today that in an independent research study published online in the Journal of Clinical Oncology, cellular levels of histone modifications define previously unrecognized subsets of patients with pancreatic cancer with distinct epigenetic phenotypes and clinical outcomes.
› Verified 1 days ago
| Entity Name | Olathe Health Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598784639 PECOS PAC ID: 7618881905 Enrollment ID: O20031119000719 |
News Archive
Verde Media Group Inc. and its Biotech Division announce they have completed the acquisition of the privately held biotechnology company Butazyme LLC.
Today, the American College of Rheumatology released the 2020 Guideline for the Management of Gout.
Claritas Genomics, Inc., announced the launch of its Claritas Clinical Exome, at the Annual Meeting of the American Society of Human Genetics running 10/6 – 10/10 in Baltimore, MD. This novel diagnostic test is the first to exploit the strengths of multiple DNA sequencing platforms simultaneously to deliver confirmed results for a patient's clinical whole exome within 4 weeks, compared to the industry standard of 12 weeks or more. Patients with rare disease typically seek a diagnosis for 8-12 years, receiving 3-5 separate tests at a high cost.
PrognosDx Health, Inc. announced today that in an independent research study published online in the Journal of Clinical Oncology, cellular levels of histone modifications define previously unrecognized subsets of patients with pancreatic cancer with distinct epigenetic phenotypes and clinical outcomes.
› Verified 1 days ago
| Entity Name | Shawnee Mission Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992735690 PECOS PAC ID: 9537119037 Enrollment ID: O20050701000310 |
News Archive
Verde Media Group Inc. and its Biotech Division announce they have completed the acquisition of the privately held biotechnology company Butazyme LLC.
Today, the American College of Rheumatology released the 2020 Guideline for the Management of Gout.
Claritas Genomics, Inc., announced the launch of its Claritas Clinical Exome, at the Annual Meeting of the American Society of Human Genetics running 10/6 – 10/10 in Baltimore, MD. This novel diagnostic test is the first to exploit the strengths of multiple DNA sequencing platforms simultaneously to deliver confirmed results for a patient's clinical whole exome within 4 weeks, compared to the industry standard of 12 weeks or more. Patients with rare disease typically seek a diagnosis for 8-12 years, receiving 3-5 separate tests at a high cost.
PrognosDx Health, Inc. announced today that in an independent research study published online in the Journal of Clinical Oncology, cellular levels of histone modifications define previously unrecognized subsets of patients with pancreatic cancer with distinct epigenetic phenotypes and clinical outcomes.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Bhaswanth Dhanireddy, MD 6601 Winchester Ave Ste 230, Kansas City, MO 64133-4681 Ph: (816) 313-2677 | Dr Bhaswanth Dhanireddy, MD 9301 W 74th St Ste 100, Shawnee Mission, KS 66204-2217 Ph: (913) 632-9100 |
News Archive
Verde Media Group Inc. and its Biotech Division announce they have completed the acquisition of the privately held biotechnology company Butazyme LLC.
Today, the American College of Rheumatology released the 2020 Guideline for the Management of Gout.
Claritas Genomics, Inc., announced the launch of its Claritas Clinical Exome, at the Annual Meeting of the American Society of Human Genetics running 10/6 – 10/10 in Baltimore, MD. This novel diagnostic test is the first to exploit the strengths of multiple DNA sequencing platforms simultaneously to deliver confirmed results for a patient's clinical whole exome within 4 weeks, compared to the industry standard of 12 weeks or more. Patients with rare disease typically seek a diagnosis for 8-12 years, receiving 3-5 separate tests at a high cost.
PrognosDx Health, Inc. announced today that in an independent research study published online in the Journal of Clinical Oncology, cellular levels of histone modifications define previously unrecognized subsets of patients with pancreatic cancer with distinct epigenetic phenotypes and clinical outcomes.
› Verified 1 days ago
Michael J Gaughan, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 9100 W 74th St, Shawnee Mission, KS 66204 Phone: 913-676-2310 | |
John Yungmeyer, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 9100 W 74th St, Shawnee Mission, KS 66204 Phone: 913-676-2310 | |
Jeffrey A Hicklin, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 9100 W 74th St, Shawnee Mission, KS 66204 Phone: 913-676-2310 | |
Richard D Miller, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 9100 W 74th St, Shawnee Mission, KS 66204 Phone: 913-676-2310 | |
Miss Kavita Chowdary Gorantla, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 9100 W 74th St, Shawnee Mission, KS 66204 Phone: 913-676-2310 | |
Michael W Dennis, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 9100 W 74th St, Shawnee Mission, KS 66204 Phone: 913-676-2310 | |
Mark S Reinsel, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 9100 W 74th St, Shawnee Mission, KS 66204 Phone: 913-599-6777 |